Background:Patients with left ventricular ejection fraction (LVEF) ≤35% are
at a high risk of sudden cardiac death (SCD) and benefit from implantable
cardioverter-defibrillator (ICD) therapy. ICD implantation is not indicated
during the first 40 days after acute myocardial infarction and <3 months
after coronary artery bypass grafting, because of possible cardiac function
recovery. The wearable cardioverter defibrillator (WCD) is a therapy option for
preventing sudden cardiac death at the time of recovery. This study evaluated
the effectiveness of the wearable cardioverter-defibrillator in preventing SCD
after cardiac surgery. Methods: This is a retrospective
study conducted in the Heart Center in Cottbus. From 02.2015 through 02.2018 26
WCD patients were retrospectively analyzed and followed-up. Patient demographics,
defibrillation treatments, and daily wear times were retrospectively obtained
from our clinical database and LifeVest network. The patients were questioned
about actual NYHA grade and implanted ICD at the end of follow-up. Results: Twenty-five
patients (mean age 65, 22 men, 3 women) were treated with a WCD in response to
heart failure (mean EF = 24%) after cardiac surgery (21 CABG, 1 AVR, 1 AVR +
CABG, 1 AVR+ MVR, MVR + CABG). Average daily use of a WCD was 22.1 (SD ± 2.7) hours
which were worn for 85 days (SD ± 35). At that time 11.96 (SD ± 15) events were
detected but not
References
[1]
Wassnig, N.K., Gunther, M., Quick, S., et al. (2016) Experience With the Wearable Cardioverter-Defibrillator in Patients at High Risk for Sudden Cardiac Death. Circulation, 134, 635-643. https://doi.org/10.1161/CIRCULATIONAHA.115.019124
[2]
Desai, A.S., Fang, J.C., Maisel, W.H. and Baughman, K.L. (2004) Implantable Defibrillators for the Prevention of Mortality in Patients with Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials. The Journal of the American Medical Association, 292, 2874-2879.
https://doi.org/10.1001/jama.292.23.2874
[3]
Epstein, A.E., Abraham, W.T., Bianco, N.R., et al. (2013) Wearable Cardioverter-Defibrillator Use in Patients Perceived to Be at High Risk Early Post-Myocardial Infarction. Journal of the American College of Cardiology, 62, 2000-2007.
https://doi.org/10.1016/j.jacc.2013.05.086
[4]
Appoo, J., Norris, C., Merali, S., et al. (2004) Long-Term Outcome of Isolated Coronary Artery Bypass Surgery in Patients with Severe Left Ventricular Dysfunction. Circulation, 110, II13-II17. https://doi.org/10.1161/01.CIR.0000138345.69540.ed
[5]
Gabrielli, D., Benvenuto, M., Baroni, M., Oliva, F. and Capucci, A. (2015) Primary Prevention of Sudden Cardiac Death through a Wearable Cardioverter-Defibrillator. Giornale Italiano di Cardiologia (Rome), 16, 418-425.
[6]
Mugnai, G., Lupo, A., Zerbo, F., Sacca, S. and Zoppo, F. (2020) Single-Center Experience with Wearable Cardioverter-Defibrillator as a Bridge before Definitive ICD Implantation. Indian Pacing and Electrophysiology Journal, 20, 60-63.
https://doi.org/10.1016/j.ipej.2019.12.010
[7]
Jiang, X., Ming, W.K. and You, J.H.S. (2019) Potential Cost-Effectiveness of Wearable Cardioverter-Defibrillator for Patients with Implantable Cardioverter-Defibrillator Explant in a High-Income City of China. Journal of Cardiovascular Electrophysiology, 30, 2387-2396. https://doi.org/10.1111/jce.14153
[8]
Masri, A., Altibi, A.M., Erqou, S., et al. (2019) Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death: A Systematic Review and Meta-Analysis. JACC: Clinical Electrophysiology, 5, 152-161.
https://doi.org/10.1016/j.jacep.2018.11.011
[9]
Bax, J.J., Visser, F.C., Poldermans, D., et al. (2001) Relationship between Preoperative Viability and Postoperative Improvement in LVEF and Heart Failure Symptoms. Journal of Nuclear Medicine, 42, 79-86.
[10]
Kutyifa, V., Moss, A.J., Klein, H., et al. (2015) Use of the Wearable Cardioverter Defibrillator in High-Risk Cardiac Patients: Data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry). Circulation, 132, 1613-1619. https://doi.org/10.1161/CIRCULATIONAHA.115.015677
[11]
Zishiri, E.T., Williams, S., Cronin, E.M., et al. (2013) Early risk of Mortality after Coronary Artery Revascularization in Patients with Left Ventricular Dysfunction and Potential Role of the Wearable Cardioverter Defibrillator. Circulation: Arrhythmia and Electrophysiology, 6, 117-128.
https://doi.org/10.1161/CIRCEP.112.973552
[12]
Adler, A., Halkin, A. and Viskin, S. (2013) Wearable Cardioverter-Defibrillators. Circulation, 127, 854-860.
https://doi.org/10.1161/CIRCULATIONAHA.112.146530
[13]
Chung, M.K., Szymkiewicz, S.J., Shao, M., et al. (2010) Aggregate National Experience with the Wearable Cardioverter-Defibrillator: Event Rates, Compliance, and Survival. Journal of the American College of Cardiology, 56, 194-203.
https://doi.org/10.1016/j.jacc.2010.04.016
[14]
Leyton-Mange, J.S., Hucker, W.J., Mihatov, N., et al. (2018) Experience with Wearable Cardioverter-Defibrillators at 2 Academic Medical Centers. JACC: Clinical Electrophysiology, 4, 231-239. https://doi.org/10.1016/j.jacep.2017.09.180
[15]
Heimeshoff, J., Merz, C., Ricklefs, M., et al. (2019) Wearable Cardioverter-Defibrillators Following Cardiac Surgery: A Single-Center Experience. The Thoracic and Cardiovascular Surgeon, 67, 92-97. https://doi.org/10.1055/s-0038-1660802
[16]
Ender, J., Borger, M.A., Scholz, M., et al. (2008) Cardiac Surgery Fast-Track Treatment in a Postanesthetic Care Unit: Six-Month Results of the Leipzig Fast-Track Concept. Anesthesiology, 109, 61-66.
https://doi.org/10.1097/ALN.0b013e31817881b3
